Cargando…
Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
Background: The association between the effectiveness of capecitabine and the concomitant administration of gastric acid suppressants remains controversial. We aimed to clarify whether the effectiveness of capecitabine is affected by the co-administration of histamine H(2) receptor antagonists (H(2)...
Autores principales: | Yamazaki, Tomoko, Uozumi, Ryuji, Kawazoe, Hitoshi, Kitazume, Yoshiko, Iihara, Hirotoshi, Fujii, Hironori, Takahashi, Masaya, Arai, Takahiro, Murachi, Yasushi, Sato, Yumiko, Mikami, Takahiro, Hashiguchi, Koji, Yoshizawa, Tomoe, Takahashi, Katsuyuki, Fujita, Yukiyoshi, Hosokawa, Yuki, Morozumi, Issei, Tsuchiya, Masami, Yokoyama, Atsushi, Hashimoto, Hironobu, Furukawa, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414027/ https://www.ncbi.nlm.nih.gov/pubmed/36046656 http://dx.doi.org/10.7150/jca.73385 |
Ejemplares similares
-
Proton pump inhibitors affect capecitabine efficacy in patients with stage II–III colorectal cancer: a multicenter retrospective study
por: Kitazume, Yoshiko, et al.
Publicado: (2022) -
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
por: Yamamoto, Senri, et al.
Publicado: (2021) -
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis
por: Yamamoto, Senri, et al.
Publicado: (2022) -
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)
por: Ozeki, Rie, et al.
Publicado: (2022) -
Low‐Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin‐Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial
por: Sakai, Chizuru, et al.
Publicado: (2021)